In a different trial, glioblastoma patients received CART-EGFR-IL13Rα2 cells targeting both EGFR and IL13Rα2 intrathecally through an intraventricular reservoir, leading to a transient regression of the tumor in all patients and early persistence of CAR T cells in the CSF [169]. This evidence concerns the gene EGFR and neoplasm.